Physician profile
Thomas Smith
NPI 1801867130
$2,956.82
in general payments reported to CMS, 2019-2025
20 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $389 · 2021: $469 · 2022: $162 · 2023: $177 · 2024: $360 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.99 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,031.52 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $722.03 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.38 | 2019-2025 | |
| Insmed, INC. | $185.57 | 2023-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $106.50 | 2019-2021 | |
| Zoll Respicardia, INC. | $85.07 | 2024 | Remede System |
| Baxter Healthcare | $80.21 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $74.69 | 2025 | Ohtuvayre |
| Inogen, INC. | $52.89 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sanofi-Aventis U.S. LLC | $34.83 | 2019-2020 | |
| Janssen Biotech, INC. | $27.68 | 2021-2022 | |
| Abbott Laboratories | $24.33 | 2025 | Diamondback Coronary |
| Gilead Sciences, INC. | $23.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.14 | 2019 | |
| Genzyme Corporation | $19.83 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $16.56 | 2025 | Amvuttra |
| Genentech USA, INC. | $16.30 | 2022 | |
| Advanced Respiratory, INC | $15.01 | 2019 | |
| Boston Scientific Corporation | $14.92 | 2023 | |
| Merck Sharp & Dohme LLC | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.